Bruker (NASDAQ:BRKR) Stock Price Down 6.5% – Here’s Why

Bruker Corporation (NASDAQ:BRKR) shares traded down 6.5% during mid-day trading on Tuesday. The stock traded as low as $59.59 and last traded at $59.7050. 430,729 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 2,351,235 shares. The stock had previously closed at $63.86.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BRKR. UBS Group assumed coverage on shares of Bruker in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 price target for the company. Zacks Research cut Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Guggenheim raised their price target on Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research report on Monday, August 31st. Finally, Citigroup cut their target price on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $58.57.

Bruker Stock Down 1.3%

The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The company’s fifty day moving average price is $58.85 and its 200-day moving average price is $52.41. The stock has a market capitalization of $9.10 billion, a PE ratio of -85.31, a price-to-earnings-growth ratio of 1.85 and a beta of 1.22.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Monday, September 21st were paid a $0.05 dividend. The ex-dividend date was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s payout ratio is presently -28.57%.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 27.20% of the company’s stock.

Institutional Trading of Bruker

Several institutional investors have recently added to or reduced their stakes in the business. Moody National Bank Trust Division purchased a new position in shares of Bruker in the third quarter worth $728,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Bruker during the 2nd quarter valued at about $250,000. Tidal Investments LLC grew its stake in shares of Bruker by 180.4% in the second quarter. Tidal Investments LLC now owns 29,092 shares of the medical research company’s stock worth $1,751,000 after acquiring an additional 18,715 shares during the period. WINTON GROUP Ltd purchased a new stake in Bruker during the 2nd quarter valued at $344,000. Finally, Engineers Gate Manager LP lifted its holdings in shares of Bruker by 141.8% during the 2nd quarter. Engineers Gate Manager LP now owns 56,825 shares of the medical research company’s stock valued at $3,420,000 after buying an additional 33,329 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company’s portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.